IL9 and neoplasm: Reasons for this discrepancy could be that (i) we used OT-II mice in this study which largely lack CD8+ T cells, the important antitumour effector cells and (ii) the beginning of administration of anti-IL-9 antibodies was on day 4 after tumour challenge in this study versus day 0 in previous studies.